

From: [Jarvis, Candace](#)
To: [James L'Italien, PhD \(jlitalien@avexis.com\)](#)
Cc: [Nancy Boman](#); [Byrnes, Andrew](#); [Jarvis, Candace](#)
Subject: BLA 125694/0 |AveXis, Inc| Information Request 48 (PLEASE RESPOND BY APRIL 19, 2019)
Date: Monday, April 08, 2019 1:51:13 PM
Attachments: [image013.png](#)

Good day Dr. L'Italien,

We have the following CMC request concerning BLA 125694/0. Please respond by April 19, 2019.

Please update your package and container label artwork in section 1.14 of the BLA as follows:

- The product should be referred to as a suspension, not a solution*
- The container label will need to indicate the license number*
- Correct the suffix on the package from (b) (4) to -xioi*

Please acknowledge receipt of this request.

Regards,

Candace N. Jarvis
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8315
candace.jarvis@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.